David-Bejker-CEO Affibody

Thu, Feb 19, 2026 23:33 CET

Medium resolution

Original resolution

Subscribe

Related Releases

Affibody’s licensee Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement Wed, Feb 18, 2026 14:28 CET